Edition:
United Kingdom

Mediwound Ltd (MDWD.OQ)

MDWD.OQ on NASDAQ Stock Exchange Global Market

4.80USD
15 Dec 2017
Change (% chg)

$0.10 (+2.13%)
Prev Close
$4.70
Open
$4.65
Day's High
$4.80
Day's Low
$4.60
Volume
25,148
Avg. Vol
9,993
52-wk High
$8.25
52-wk Low
$4.20

Chart for

About

MediWound Ltd. is a biopharmaceutical company. The Company focuses on developing, manufacturing and commercializing therapeutics products in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. The Company's product, NexoBrid, is indicated for the removal of dead... (more)

Overall

Beta: 0.04
Market Cap(Mil.): $135.72
Shares Outstanding(Mil.): 26.35
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.14 16.44
EPS (TTM): -- -- --
ROI: -- 14.86 10.62
ROE: -- 16.28 14.20

BRIEF-MediWound Q3 loss per share $0.49

* Q3 earnings per share view $-0.19 -- Thomson Reuters I/B/E/S

16 Nov 2017

BRIEF-Tel Aviv district court ordered Mediwound to purchase about $1.5 mln of PolyHeal shares

* Tel Aviv district court ordered Mediwound to purchase approximately $1.5 million of PolyHeal shares; Mediwound weighing an appeal

14 Nov 2017

BRIEF-MediWound appoints Mr. Stephen T. Wills as chairman

* MediWound appoints Mr. Stephen T. Wills as chairman to its Board of Directors

25 Oct 2017

BRIEF-MediWound Ltd announces new distribution agreement with Holy Stone Healthcare for NexoBrid

* MediWound Ltd - ‍ announced an agreement with Holy Stone Healthcare, co for distribution of Nexobrid in Taiwan for treatment of severe burns​ Source text for Eikon: Further company coverage:

16 Oct 2017

BRIEF-MediWound announces pricing of $22 million public offering of ordinary shares

* MediWound announces pricing of $22 million public offering of ordinary shares

19 Sep 2017

BRIEF-MediWound Ltd files for stock shelf offering; size ‍​not disclosed - SEC Filing

* MediWound Ltd files for stock shelf offering; size ‍​not disclosed - SEC Filing Source text: [http://bit.ly/2fuY54X] Further company coverage:

18 Sep 2017

BRIEF-MediWound Ltd announces public offering of ordinary shares

* MediWound Ltd. announces public offering of ordinary shares

18 Sep 2017

BRIEF-MediWound successfully completes second cohort of EscharEx phase 2 study

* MediWound successfully completes second cohort of EscharEx phase 2 study

01 Sep 2017

BRIEF-Mediwound reports Q2 loss per share $0.20

* Q2 earnings per share view $-0.20 -- Thomson Reuters I/B/E/S

03 Aug 2017

BRIEF-BARDA upsizes contract with MediWound and exercises option to fund further NexoBrid indications

* BARDA upsizes contract with MediWound and exercises option to fund further NexoBrid® indications

19 Jul 2017

Earnings vs. Estimates